TrialOncology research2021

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.

Tsung-Kun Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.